8 Patents
- US125761482026Engineered Immune Effector Cells for Cancer Immunotherapy That Are Resistant to Fratricide by Virtue of Having Genetically Modified Surface Antigens
Mitenyi Biotec B.V. & Co. Kg
0 cites - US123659162025Adapter-based Retroviral Vector System for the Selective Transduction of Target Cells
MILTENYI BIOTEC B.V. & Co. KG
0 cites - US123184462025Reducing Side Effects of Immunotherapy Using Genetically Modified Hematopoietic Cells
Miltenyi Biotec B.V. & Co. Kg
0 cites - US122460652025Immunotherapy of Cancer Patients Using CAR T or CAR NK Cells Combined with Hematopoietic Cells That Have a Modified or Deleted Target Antigen
Miltenyi Biotec B.V. & Co. Kg
0 cites - US121788722024Regulatory T Cell Expressing a Chimeric Antigen Receptor
Charité—universitätsmedizin Berlin
0 cites - US120182732024CD62L Specific Lentiviral Vector Particle for Targeted Transduction of T Cell Subsets
Miltenyi Biorec B V. Co., KG
0 cites - US118903002024Immune Cells Expressing an Antigen Binding Receptor and a Chimeric Costimulatory Receptor
Miltenyi Biotec B.V. & Co. KG
0 cites - US118834942024Combination of Immune Effector Cells Specific for a Target Antigen and Hematopoietic Calls That Express the Target Antigen in an Altered Form
MILTENYI BIOTEC B.V. & Co. KG
0 cites